Real World Efficacy of Pembrolizumab of as a 1st Line Treatment in Metastatic Non-Small Cell Lung Cancer with PD-L1 High Expression

被引：0
|
作者：
Kasahara, K. [1 ]
Sone, T. [1 ]
Nishi, K. [2 ]
Shibata, K. [3 ]
Araya, T. [4 ]
Shirasaki, H. [5 ]
Yoneda, T. [6 ]
Kase, K. [7 ]
Nishikawa, S. [1 ]
Kimura, H. [1 ]
Tambo, Y. [1 ]
机构：
[1] Kanazawa Univ, Resp Med, Kanazawa, Ishikawa, Japan
[2] Ishikawa Prefectural Cent Hosp, Resp Med, Kanazawa, Ishikawa, Japan
[3] Kouseiren Takaoka Hosp, Med Oncol, Takaoka, Toyama, Japan
[4] Natl Hosp Org Kanazawa Med Ctr, Resp Med, Kanazawa, Ishikawa, Japan
[5] Fukui Ken Saiseikai Hosp, Resp Med, Fukui, Japan
[6] Komatsu Municipal Hosp, Resp Med, Komatsu, Japan
[7] Keiju Med Ctr, Resp Med, Nanao, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Pembrolizumab; 1st line treatment; PD-L1 high expression;
D O I：
10.1016/j.jtho.2019.08.953
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.04-50
引用
收藏
页码：S460 / S460
页数：1
相关论文
共 50 条
  • [1] Real World Experience of 1st Line Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Ansel, S.
    Mcloone, P.
    Steele, N.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S926 - S926
  • [2] Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer
    Thu Oanh Dang
    Ogunniyi, Adebayo
    Barbee, Meagan S.
    Drilon, Alexander
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (01) : 13 - 20
  • [3] First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
    Zhou, Yixin
    Lin, Zuan
    Zhang, Xuanye
    Chen, Chen
    Zhao, Hongyun
    Hong, Shaodong
    Zhang, Li
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [4] Current status of first-line treatment with pembrolizumab for non-small-cell lung cancer with high PD-L1 expression
    Ikezawa, Yasuyuki
    Mizugaki, Hidenori
    Morita, Ryo
    Tateishi, Kazunari
    Yokoo, Keiki
    Sumi, Toshiyuki
    Kikuchi, Hajime
    Kitamura, Yasuo
    Nakamura, Atsushi
    Kobayashi, Maki
    Aso, Mari
    Kimura, Nozomu
    Yoshiike, Fumiaki
    Furuta, Megumi
    Tanaka, Hisashi
    Sekikawa, Motoki
    Hachiya, Tsutomu
    Nakamura, Keiichi
    Shimokawa, Mototsugu
    Oizumi, Satoshi
    CANCER SCIENCE, 2022, 113 (06) : 2109 - 2117
  • [5] Gene expression profile of high PD-L1 non-small cell lung cancers refractory to pembrolizumab
    Jamila Talb
    Paul Takam Kamga
    Marie Mayenga
    Adrien Costantini
    Catherine Julié
    Coraline Dumenil
    Jennifer Dumoulin
    Julia Ouaknine
    Violaine Giraud
    Cécile Dujon
    Reza Azarian
    Claire Glaser
    Jean-François Emile
    Etienne Giroux Leprieur
    Cancer Immunology, Immunotherapy, 2022, 71 : 2791 - 2799
  • [6] Gene expression profile of high PD-L1 non-small cell lung cancers refractory to pembrolizumab
    Talb, Jamila
    Kamga, Paul Takam
    Mayenga, Marie
    Costantini, Adrien
    Julie, Catherine
    Dumenil, Coraline
    Dumoulin, Jennifer
    Ouaknine, Julia
    Giraud, Violaine
    Dujon, Cecile
    Azarian, Reza
    Glaser, Claire
    Emile, Jean-Francois
    Leprieur, Etienne Giroux
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (11) : 2791 - 2799
  • [7] Cost-Effectiveness of Pembrolizumab as 1st Line Treatment for Metastatic NSCLC Patients with High PD-L1 Expression in Singapore
    Tan, W. L.
    Huang, M.
    Chandwani, S.
    Hsu, T.
    Tan, S. C.
    Tan, D.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S630 - S630
  • [8] Real-world comparative effectiveness and safety of pembrolizumab for PD-L1≥50% metastatic non-small-cell lung cancer
    Parmar, Ambica
    Lu, Brandon
    Luo, Jin
    Chan, Kelvin K.
    FUTURE ONCOLOGY, 2024, 20 (36) : 2879 - 2888
  • [9] Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression
    Wakuda, Kazushige
    Yabe, Michitoshi
    Kodama, Hiroaki
    Nishioka, Naoya
    Miyawaki, Taichi
    Miyawaki, Eriko
    Mamesaya, Nobuaki
    Kawamura, Takahisa
    Kobayashi, Haruki
    Omori, Shota
    Ono, Akira
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Murakami, Haruyasu
    Harada, Hideyuki
    Endo, Masahiro
    Gon, Yasuhiro
    Takahashi, Toshiaki
    LUNG CANCER, 2021, 151 : 60 - 68
  • [10] PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer
    Miyawaki, Eriko
    Murakami, Haruyasu
    Mori, Keita
    Mamesaya, Nobuaki
    Kawamura, Takahisa
    Kobayashi, Haruki
    Omori, Shota
    Wakuda, Kazushige
    Ono, Akira
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Takahashi, Toshiaki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (05) : 617 - 622
12345